Finally, we examined whether MET aberrations had a prognostic impact or predicted likelihood of response to chemotherapy by comparing two groups of MM patients with and without MET overexpression treated at our institution during 2015–2017, i.e., with a minimum 3 years of follow-up. The gene discussed is MET; the disease is Miyoshi myopathy.